Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay (Q42211136)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 19 June 2014

Language	Label	Description	Also known as
English	Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay	scientific article published on 19 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

0 references

1 reference

based on heuristic

inferred from title

Françoise Brun-Vézinet

7

object named as

Françoise Brun-Vézinet

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Gilles Peytavin

9

object named as

Gilles Peytavin

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

10

object named as

Diane Descamps

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Charlotte Charpentier

1

object named as

Charlotte Charpentier

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yazdan Yazdanpanah

8

object named as

Yazdan Yazdanpanah

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

11

object named as

Roland Landman

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Benoit Visseaux

5

object named as

Benoit Visseaux

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

4

object named as

Patrick Yeni

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

author name string

Marion Choquet

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Véronique Joly

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Marion Caseris

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

language of work or name

0 references

publication date

19 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

2819-2825

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Identifiers

10.1093/JAC/DKU211

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42211136&oldid=2080126195"